News
I'm Buying These 3 Resilient Stocks During a Bear Market
There is a difference of opinion about whether the economy is headed for a recession or perhaps already coming out of one, depending on what metrics are used. That can be confusing for investors
Is Pfizer Stock a Buy Now?
A year ago, Pfizer (NYSE: PFE) was soundly beating the market, racking up highly impressive sales thanks to its COVID-19 products. But with the pandemic no longer a global health crisis per guidance
Is Pfizer Stock a Buy Now?
A year ago, Pfizer (NYSE: PFE) was soundly beating the market, racking up highly impressive sales thanks to its COVID-19 products. But with the pandemic no longer a global health crisis per guidance
2 Dividend Stocks That Just Raised Their Payouts by More Than 10%
If you're investing in dividend stocks, you should prioritize investments that increase their payouts. That way, the recurring dividend income you receive can potentially stay ahead of inflation.
A
2 Dividend Stocks That Just Raised Their Payouts by More Than 10%
If you're investing in dividend stocks, you should prioritize investments that increase their payouts. That way, the recurring dividend income you receive can potentially stay ahead of inflation.
A
2 No-Brainer Healthcare Stocks to Buy Right Now
Investors looking to participate in the stock market have a multitude of options, and it can sometimes be hard to separate the wheat from the chaff. But some companies look especially attractive
3 AI Stocks not Named Nvidia That Have Doubled This Year
Nvidia attracted plenty of investor excitement this year thanks to the increased hype surrounding artificial intelligence (AI). That excitement was enough to help it exceed a $1 trillion market cap
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Alleged Industrial Espionage Makes an Interesting Story
In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:
Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at
Alleged Industrial Espionage Makes an Interesting Story
In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:
Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at
Alleged Industrial Espionage Makes an Interesting Story
In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:
Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at
Why Shares of Patterson Companies Shot Up Wednesday
Shares of Patterson Companies (NASDAQ: PDCO) were up 14.7% Wednesday afternoon after rising as much as 28.3%, hitting a 52-week high of $32.82. The healthcare company, which makes products and
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
Over the last couple of weeks, Cathie Wood's ARK Innovation ETF has been busy buying shares of gene-editing biotech Intellia Therapeutics (NASDAQ: NTLA). She's also been selling some shares of
History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever
Over time, stocks with growing dividends and high returns on invested capital (ROICs) have tended to outperform their peers. By highlighting these qualities -- plus a payout ratio below 50% --
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching
This Healthcare Stock Is Sending More Cash to Its Shareholders: Should You Buy It?
The primary objective of dividend growth investing is to build an investment portfolio that can provide an investor with reliable and growing streams of passive income. The dividends can be used
1 Growth Stock Down 66% to Buy Right Now
Ideally, growth stocks are supposed to, well, grow. But that doesn't always happen.
Sometimes, even the best stocks experience steep downturns. The good news is that these sell-offs present great
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is CRISPR Therapeutics Stock a Buy Now?
An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration
Is CRISPR Therapeutics Stock a Buy Now?
An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration
Is CRISPR Therapeutics Stock a Buy Now?
An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration
Why Quotient Technology Stock Was Up on Tuesday
Quotient Technology (NYSE: QUOT) shareholders had a great to start to the trading week. The digital promotions and media tech specialist's stock jumped 16% in early trading, compared to a nearly 1%
After Blasting Off 881% in 1 Year, Is Viking Therapeutics Still a Good Buy?
Viking Therapeutics (NASDAQ: VKTX) is up 881% in the last 12 months thanks to its ongoing development of a pair of therapies to treat obesity and metabolic disorders like diabetes. As you may have